Supernus Pharmaceuticals (SUPN) Set to Announce Quarterly Earnings on Wednesday

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) will be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). The company had revenue of $164.30 million during the quarter, compared to analyst estimates of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. Supernus Pharmaceuticals's quarterly revenue was down 1.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 EPS. On average, analysts expect Supernus Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Supernus Pharmaceuticals Price Performance

SUPN stock traded down $0.02 during trading on Wednesday, hitting $30.08. The company had a trading volume of 394,210 shares, compared to its average volume of 377,392. The company has a fifty day moving average price of $31.60 and a two-hundred day moving average price of $28.70. Supernus Pharmaceuticals has a fifty-two week low of $21.99 and a fifty-two week high of $38.09.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 28th.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,884 shares of the business's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now owns 8,570 shares of the company's stock, valued at $282,724.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, VP Padmanabh P. Bhatt sold 3,884 shares of the business's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total transaction of $128,133.16. Following the completion of the sale, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the business's stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the sale, the vice president now owns 8,570 shares of the company's stock, valued at approximately $302,606.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,739 shares of company stock valued at $1,227,433. 8.76% of the stock is currently owned by corporate insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.